Axsome Logo.png
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference
September 01, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Axsome Logo.png
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
August 23, 2021 06:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Logo.png
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
August 09, 2021 07:00 ET | Axsome Therapeutics, Inc.
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
April 26, 2021 06:00 ET | Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day
March 24, 2021 08:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 17, 2021 07:00 ET | Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
December 08, 2020 06:00 ET | Axsome Therapeutics, Inc.
68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
December 02, 2020 06:00 ET | Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
December 01, 2020 06:00 ET | Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...